Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Zoledronic Acid; Letrozole · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Zoledronic Acid; Letrozole | DRUG | - |
Inclusion Criteria * Postmenopausal women * Newly diagnosed with non metastatic breast cancer * Candidate for mastectomy or breast-conserving surgery Exclusion Criteria * Patients with invasive tumors * Patients receiving anti-cancer treatment * Patients who have undergone surgery Other protocol...
Top 20 of 92 competitors
Zoledronic Acid; Letrozole is a combination of two small molecule drugs being studied as neoadjuvant therapy for early breast cancer in women aged 65 years and older. The combination is intended to be given before primary treatment to assess its effects on the tumor.
Zoledronic Acid; Letrozole is being developed by Novartis AG, which trades under the ticker NVS. The company is conducting clinical research on this combination for the treatment of breast cancer.
Zoledronic Acid; Letrozole is in Phase 2 clinical development. It is an investigational combination and has not been approved by regulatory authorities. One Phase 2 trial has been completed, with no active trials currently ongoing.
Zoledronic Acid; Letrozole has been studied in one completed Phase 2 trial, NCT00247650, which compared letrozole alone to letrozole with zoledronic acid in early breast cancer as neoadjuvant therapy. The trial enrolled 190 women aged 65 years and older in Canada.
No, Zoledronic Acid; Letrozole is a combination of two drugs, zoledronic acid and letrozole, whereas letrozole alone is a single agent. The clinical trial NCT00247650 was designed to compare the combination against letrozole monotherapy in early breast cancer.